.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Queensland Health
Boehringer Ingelheim
Chubb
QuintilesIMS
Argus Health
Harvard Business School
Express Scripts
Baxter
Johnson and Johnson

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,998,402

« Back to Dashboard

Which drugs does patent 5,998,402 protect, and when does it expire?


Patent 5,998,402 protects DUAVEE and is included in one NDA.

This patent has thirty-nine patent family members in twenty-nine countries.

Summary for Patent: 5,998,402

Title: 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
Abstract:The present invention relates to new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below: ##STR1##
Inventor(s): Miller; Chris P. (Strafford, PA), Collini; Michael D. (Clifton Heights, PA), Tran; Bach D. (Media, PA), Santilli; Arthur A. (Havertown, PA)
Assignee: American Home Products Corporation (Madison, NY)
Application Number:08/833,271
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Wyeth Pharms PfizerDUAVEEbazedoxifene acetate; estrogens, conjugatedTABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► SubscribeYYPREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,998,402

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,041,6632-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
7,449,4552-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,326,367 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,951,852 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indoles as estrogenic agents► Subscribe
6,127,404 Tissue selective compounds in the treatment of endometrial proliferation► Subscribe
6,835,729 2-phenyl-1-[4(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
7,132,4172-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,787,538 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,291,451 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
7,247,6242-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,998,402

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan381093► Subscribe
Slovakia281737► Subscribe
Slovakia47297► Subscribe
Slovenia802183► Subscribe
Portugal802183► Subscribe
New Zealand314601► Subscribe
Norway2009025► Subscribe
Norway309564► Subscribe
Norway971815► Subscribe
Netherlands300416► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Covington
Argus Health
AstraZeneca
Citi
Fuji
Moodys
Healthtrust
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot